July 20, 2021

Jason Krantz Chief Executive Officer Definitive Healthcare Corp. 550 Cochituate Rd Framingham, MA 01701

Re: Definitive

Healthcare Corp.

Amendment No. 1 to

Draft Registration Statement on Form S-1

Submitted June 30,

2021

CIK No. 0001861795

Dear Mr. Krantz:

We have reviewed your amended draft registration statement and have the following  $\boldsymbol{\theta}$ 

comments. In some of our comments, we may ask you to provide us with information so we

may better understand your disclosure.

Please respond to this letter by providing the requested information and either submitting

an amended draft registration statement or publicly filing your registration statement on  $% \left( 1\right) =\left( 1\right) +\left( 1\right) +$ 

EDGAR. If you do not believe our comments apply to your facts and circumstances or do not

believe an amendment is appropriate, please tell us why in your response.

 $\qquad \qquad \text{After reviewing the information you provide in response to these comments and your } \\$ 

amended draft registration statement or filed registration statement, we may have additional  $% \left( 1\right) =\left( 1\right) +\left( 1\right$ 

comments. References to prior comments are to those in our letter dated June 24, 2021.

Amendment No. 1 to Draft Registration Statement on Form S-1 filed June  $30,\ 2021$ 

Prospectus Summary, page 1

1. We note your response to prior comment 1. Because the charts on page 3 and 83 continue to show the company revenues in fiscal 2019 and 2020, please add the company's net losses for those years to balance the disclosure.

Summary Historical and Pro Forma Consolidated Financial and Other Data Other Financial Data , page 19

2. For each of Adjusted EBITDA, Adjusted Gross Profit, Adjusted Gross Margin, Adjusted Operating (loss)
Income, and Adjusted EBITDA Margin, please present with equal or greater prominence, the

most directly comparable financial measure respectively

Jason Krantz

Definitive Healthcare Corp.

July 20, 2021

Page 2

calculated and presented in accordance with GAAP. Include a reconciliation of Adjusted  $\,$ 

EBITDA Margin to its most comparable GAAP ratio in Non-GAAP Financial Measures

which you referenced in footnote (1) hereunder. Refer to Item 10(e)(1)(i)(A) - (B) of

Regulation S-K and footnote 27 of the SEC s Adopting Release titled Conditions for Use

of Non-GAAP Financial Measures (Release No. 33-8176). Unaudited Pro Forma Consolidated Balance Sheet (As of , 2021)

Notes to Unaudited Pro Forma Consolidated Balance Sheet (as of , 2021), page 82

3. We note in your response to comment 6 the Company presents the contingently  ${\sf Company}$ 

redeemable non-controlling interest as permanent equity because the Company and not the  $\,$ 

holders determines whether to satisfy a redemption request from a holder of LLC Units in

will make the decision to issue shares or pay cash. In this regard, we note the  $\ensuremath{\mathsf{Pre-}}$ 

 $\,$  IPO LLC Members will be able to control any action requiring the general approval of

your stockholders including the election of your board of directors. A board member,

while considered independent for regulatory compliance purposes, may not be considered  $% \left( 1\right) =\left( 1\right) \left( 1\right) +\left( 1\right) \left( 1\right) \left( 1\right) +\left( 1\right) \left( 1\right)$ 

independent for accounting purposes if that member was appointed to the board by  $% \left( 1\right) =\left( 1\right) \left( 1\right) +\left( 1\right) \left( 1\right) \left( 1\right) +\left( 1\right) \left( 1\right$ 

individuals who currently hold Class B common stock and Common Units. Executive and Director Compensation

Class B Unit Agreements with Messrs. Krantz, Shone and Mirisola, page 135

4. We note your response to comment 13. Please disclose any compensation cost arising

from the modification of performance-vesting Class B Units into an award of restricted common units.

You may contact Kathryn Jacobson, Senior Staff Accountant, at (202) 551-3365 or

Robert Littlepage, Accounting Branch Chief, at (202) 551-3361 if you have questions regarding

comments on the financial statements and related matters. Please contact Matthew Crispino,

Staff Attorney, at (202) 551-3456 or Larry Spirgel, Office Chief, at (202) 551-3815 with any other questions.

FirstName LastNameJason Krantz Comapany NameDefinitive Healthcare Corp. Sincerely,

Corporation Finance July 20, 2021 Page 2 Division of

Technology
FirstName LastName

Office of